TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    Translating Aging

    On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.

    Advertise

    Copyright: © Copyright 2021 BioAge Labs

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    DISCO: A New Model for Entrepreneurship in Longevity Biotech (Dr. James Peyer — Cambrian Biopharma) Dec 01, 2021
    Show notes

    Dr. James Peyer, PhD, is the Founder and CEO of Cambrian Biopharma, a Distributed xDevelopment Company developing therapeutics targeting the biological drivers of aging.

    Cambrian Biopharma brings together experts, scientists, and experienced company builders in a new model of entrepreneurship related to health span and aging. Dr. Peyer was previously the founder of Apollo Ventures, a successful venture capital firm focused on the longevity biotech space. He has spoken on the topic of longevity biotech and investing for Bloomberg, The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging.

    Today, Dr. Peyer joins host Chris Patil to discuss venture capitalism in the longevity space and the new models that are changing the game. After discussing his previous experiences with VC, Dr. Peyer introduces the Distributed Development Company (DISCO) model, which allows scientists to partner with an umbrella company (like Cambrian) instead of selling their discovery to a pharma company. He explains how this model allows investors to support scientists through the whole process of drug development, from initial idea to commercialization, while prioritizing the quality of the science above everything else. Dr. Peyer then goes on to give some details about Cambrian’s success so far and how it sources and supports up-and-coming talent in the longevity field. He finishes up by making some predictions about the future of biotech companies and how the DISCO model will have a big role to play.

    In this episode, you’ll learn about venture capitalism’s role in scientific discovery and development and why Dr. Peyer believes a new model is necessary to remove the inefficiencies in the current process.

    Episode Highlights:

    · Dr. Peyer’s experience with Apollo Ventures and why he’s moved on to Cambrian Biopharma

    · The future of the longevity space will come in two stages: reusing insights into what makes us age to build drugs for today, and using those safe and effective drugs to slow down the rate of aging in healthy people

    · In the long run, company-based models will be better than fund-based ones for the longevity space

    · The Distributed Development Company model (aka DISCO)

    · Cambrian started with three programs and has scaled up to over fourteen in two years

    · Cambrian prioritizes the quality of the science over hype

    · Cambrian has raised about $160 million since 2019, including $100 million Series C financing at the end of October

    · Cambrian sources talent through constant monitoring of the scientific field

    · The DISCO model was designed to correct inefficiencies in the process of getting funding for scientists and their discoveries

    · Drug development is a risky process, and Cambrian ensures success by carefully monitoring progress at every stage

    · Being a bona fide longevity biotech organization means being willing to support every single program from funding to commercialization

    · There are opportunities to partner with big pharma companies, but commitment to the whole process is the default

    · Cambrian’s two publicly-disclosed programs are with Vita Therapeutics, a cell engineering company run out of Johns Hopkins

    · One of the advantages Cambrian can provide to scientists is the ability to keep their discoveries as trade secrets as long as possible to maximize their patent lifespan

    · The potential for the DISCO model to be used in other fields beyond longevity

    · The possibility of failure and how Cambrian works to avoid it by being realistic and strategic and bringing expertise on board

    · DISCO works really well for asset-centric breakthroughs made by very small companies or at universities, but it’s not the catch-all solution for everything—for example, tech platforms may be a better choice for bigger biotechs, while founder-led biotechs are better for young entrepreneurs

    · External factors in aging

    · Predictions for the field ten years from now

    Quotes:

    “I like to say that we get to take the best parts of being a VC, a pharma company, and an entrepreneurial biotech, and very few of the negatives.”

    “When we raise capital into Cambrian, what we get to do is we have our Cambrian team, which cares exclusively about the quality of the science, right? Not the hype or the number of Twitter likes around some particular discovery, but exclusively about the quality of the science.”

    “Cambrian breaks apart the existing longevity biotech field at the academic level, into thirteen different focus areas that we are constantly monitoring.”

    “I think that our model was designed to correct some of the inefficiencies that happen for scientists and scientific founders first, and it also is a happy accident that that model is also, I think, the more investable and more scalable one.”

    “Creating an organization that can really assess a group on whether it’s sink or swim based on the science and not the ability to raise money, I think has been a huge advantage for us.”

    “The reality of the situation is when a drug starts its first human clinical trial, there is about a 10% chance that it will ultimately make it to approval. And if you select just on, like, venture-backed biotechs from really smart groups, that number only goes up to about 15-16%.”

    “With every single program that we get involved with, if the science continues to look great, that means we are going to be there with that group, providing the funding, the organizational structure, everything to see that all the way through to commercialization.”

    “The value of any drug is driven essentially by its patent life.”

    “Models like the DISCO model that we’re using with Cambrian are actually going to replace a big chunk of early-stage venture capital in the biotech space and particularly for asset-centric companies.”

    “I sometimes call this model of biotech, the ‘hungry beast’ model of building biotechs.”

    “We’re just much more hands-on, right? We want to be doing the research and development, and the funding, and a lot of the strategy, together with the scientists that we start things with, which doesn’t fit for everybody.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Cambrian Biopharma Homepage


    Big Data and Human Health & Longevity (Prof. Michael Snyder — Stanford Medicine) Nov 10, 2021
    Show notes

    Professor Michael Snyder is the Chair of Genetics at Stanford School of Medicine, where his research group develops and uses technologies to study biological regulatory networks and applies these approaches to understand human variation and health. He's founded multiple biotech startups and has authored a book titled Genomics and Personalized Medicine: What Everyone Needs to Know.

    Today, Professor Snyder joins host Bob Hughes to discuss the impact of big data on human health. He reviews the results of his research, carried out on 109 people including himself, which entails collecting numerous types of health data and building an informative data profile, as opposed to the traditional approach of collecting just a few pieces of information. He goes on to share his personal story of how collecting deep data on himself helped him change his lifestyle after being diagnosed as a type two diabetic - using precision medicine to control diabetes. Professor Snyder also explores how DNA methylation can be used to track aging patterns and ageotypes, as well as the relationship between aging and Big Data collection, and also discusses health and longevity from his viewpoint, particularly from the standpoint of boosting the immune system.

    In this episode, you’ll learn how Big Data can influence our health, and why Professor Snyder believes that the transformation of healthcare begins with deep-diving into data.

    Episode Highlights:

    ● Understanding precision medicine and personalized medicine

    ● How Big Data influences individual health

    ● Professor Snyder’s research results on 109 people

    ● The impacts of deep data profiles

    ● How Professor Snyder changed his lifestyle after deep-diving into his data

    ● Using precision medicine to control diabetes

    ● DNA Methylation and tracking aging patterns

    ● Selection criteria for the 109 research subjects

    ● Professor Snyder’s growth over the years from yeast biology

    ● Human health and longevity from Professor Snyder’s viewpoint

    Quotes:

    “We're actually much more focused, I would say, on precision health, trying to keep people healthy at an individualized level, and trying to use big data to do just that.”

    “We're in a world now where you can just collect so much deeper data on people.”

    “I liken it to a jigsaw puzzle. If I want to see what the picture is in a puzzle, looking at one or two pieces of a 1000 person puzzle isn't going to tell me the picture, even 15 pieces probably won't do it. But I want to look at as many pieces as possible. And that's what big data is all about.”

    “One aspect is to collect data, the other is to do it over time.”

    “A lot of people who survived the COVID infections wind up being type two diabetics on a 4% increase, which is a pretty large number of people.”

    “Everybody has different aging patterns, and so the way we think about this is like a car. Your car as a whole gets older over time, but some parts wear out first. ”

    “Having good biomarkers for aging, we think, is a big deal.”

    “Why are we measuring 15 things? We should be measuring thousands.”

    “There's a ton of investment going into longevity these days - billions of dollars now into these new startups.”

    “Your immune system starts plummeting in your 60s, as I say, and that just leaves you more and more vulnerable anytime after that.”

    “I think we can transform healthcare. I think you'll see big changes in the next 10 years in terms of home testing, all this sort of stuff.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    The Snyder Lab

    Genomics and Personalized Medicine: What Everyone Needs to Know


    Accelerating drug discovery for aging and its diseases (Ben Kamens - Spring Discovery) Oct 27, 2021
    Show notes

    Ben Kamens is the founder and CEO of Spring Discovery, a company devoted to accelerating therapies for aging and its diseases. Prior to that, Ben was the first engineer for Khan Academy, which provides free online education to millions of users around the world. Today Ben joins host Chris Patil to discuss Spring Discovery’s mission to increase healthy lifespan and dramatically reduce disease, his experience with Khan Academy and how it connected to his work in biotechnology, and overcoming challenges in the field of aging.

    Ben tells Chris about his pragmatic approach to building a company, how Spring Discovery plans to accelerate drug discovery and clinical development, and their collegial relationship with BioAge and other companies in the longevity biotech sector. Ben chats about Spring Discovery’s recent Series B funding, then offers a sneak peek into their therapeutic pipeline, and details his experience running a nonprofit clinical trial for a generic drug to fight against COVID, including what this taught him about testing drugs for age-related indications. Finally, Ben shares his favorite aspect of longevity science that his company is not currently working on, and where he sees the field of aging moving toward over the next five to ten years.


    To learn more about Ben and Spring Discovery’s work to accelerate drug discovery with machine learning, visit springdiscovery.com.


    Episode Highlights:

    • Ben Kamens is the founder and CEO of Spring Discovery; he was also the first engineer for Khan Academy
    • Introduction to Spring Discovery and how recent Series B funding will help the company advance its work to increase healthy lifespan and dramatically reduce disease
    • His initial skepticism and passion for fighting disease
    • Overcoming obstacles in the field of aging
    • Building value and resources as a company over time
    • Accelerating drug discovery and clinical development
    • Machine learning approach
    • Spring Discovery’s therapeutic pipeline
    • Ben’s involvement running a nonprofit clinical trial for a generic drug against COVID, and what this taught him about testing drugs for age-related indications
    • You can read Ben’s article “COVID-19 is the latest disease to point at our need to treat immune aging” here
    • Favorite aspect of longevity science that his company is not currently working on


    Quotes:

    “I couldn't think of a more important mission to try to enable than battling diseases of aging. And our mission is to give the best technology possible to these people who are doing what we think is the most important work possible.”


    “I came to this field as an outsider and somebody who's really a team builder, and interested in deploying the intersection of scientists and technology to try to fight disease.”


    “I am an extremely pragmatic person, especially when it comes to company building and entrepreneurialism.”


    “When you mention aging, you're immediately talking about this extremely broad array of biological phenomena, some of which are going to be relevant clinically, some of which are not.”


    “This presented a real opportunity to build the best company in the world at measuring the many changes that occur in us as we age.”


    “We've essentially taken an engineering throughput mindset to disentangling the many dimensions of age-related changes that accrue in our cells and tissues over time, and built a company around getting really, really good at that, and then using that to much more quickly search for therapies.”


    “You can think of it as a big engine that takes in a whole bunch of primary human samples, spits out this very multidimensional, complete view of cellular function, but does it in a big single screen that's combining tons of phenotypic imaging data with proteomics data, and then uses a set of models we built up to identify different cellular functions that are being identified in that raw data.”


    “I do not view that as competition whatsoever. I have nothing but respect for BIOAGE.”


    “We can cause all sorts of problems for ourselves. I don't really know what a competitor would do that would really dramatically change our trajectory.”


    “Our current focus is in the world of immune aging, and specifically how immune aging applies to both the pulmonary and skin therapeutic areas.”


    “We were following our standard path. And then, as you know, the more data that came out, the more it became very obvious that, more so than any other comorbidity, one's age defined one’s outcome with COVID. And it was almost looking like people who are much older who get COVID have an entirely different disease than people who are much younger.”


    “For most diseases, they are way worse for you if you're older, and so where is all the therapeutic effort that is focused on that huge fact in COVID?”


    “I am very uniquely proud that we found a way to do this.”


    “For me, this was just validation that there are ways to run pragmatic, cost effective, timely clinical trials for diseases that are exacerbated by the biology of aging.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Spring Discovery Website springdiscovery.com



    The naked mole rat: A model of successful aging (Dr. Rochelle Buffenstein — Calico Life Sciences) Oct 13, 2021
    Show notes

    Rochelle Buffenstein is one of the world’s leading authorities on the naked mole rat, a fascinating animal that has emerged as an important model for research in longevity science. Dr. Buffenstein is currently a senior principal investigator at Calico Life Sciences, a subsidiary of Alphabet, that is seeking to better understand the biology that controls aging and lifespan.

    Today Dr. Buffenstein joins host Bob Hughes to explain why the naked mole rat is such a powerful model of successful aging. She talks about their resistance to cardiovascular disease, cancer, and neurodegeneration, and what this means for improving human health. You’ll hear about the role of Nrf-2 signaling in maintaining optimal health, looking beyond common animal model systems to understand aging more deeply, and the advantages of looking at health and longevity in naked mole rats versus mice. Dr. Buffenstein also discusses the typical hallmarks of aging and inflammation as they present in the naked mole rat, their unusual reproductive activity, and what this can teach us about human fertility.


    In this episode, you’ll learn why this unique and resilient creature is a “super organism” of sorts, and why Dr. Buffenstein believes they contain the blueprint for how to live long and successfully healthy lives.


    Episode Highlights:

    • Introduction to naked mole rat as a powerful model of successful aging
    • How Dr. Buffenstein came to study these animals and what is unique about their aging process
    • Naked mole rat’s reduced susceptibility to cardiovascular disease and cancer
    • Research on whether they are resistant to neurodegeneration
    • Central mechanism that provides generalized protection may be at play
    • Nrf-2 signaling pathway and its role in maintaining optimal health
    • Thinking beyond common model systems to learn about molecular processes of aging
    • Studying aging in a long-lived system is more pertinent to humans
    • Advantages of looking at slow aging process in a natural context
    • The Methuselah Mouse Prize (Mprize) is being offered to the first person who can make mice live longer than five years
    • Ultimate cause of death in naked mole rats is unknown
    • Hallmarks of aging and inflammation process as they relate to naked mole rat
    • Naked mole rats lack natural killer cells, which are very important for fighting viruses
    • Innate and adaptive immune systems
    • Unusual reproductive activity for naked mole rats
    • They have adapted to a particularly harsh and hostile environment
    • Dr. Buffenstein believes they contain the blueprint for how to stave off many of the adverse effects of aging


    Quotes:

    “A naked mole rat is a mouse-sized rodent that stands out as an especially powerful model of successful aging, primarily because it is known to live an incredibly long time. It seems to be exceptionally resistant to most age-associated diseases like cancer and cardiovascular disease. And even reproductive senescence.”


    “We believe that given this phenotype that these animals are a very good example that aging does not need to be inevitable, and that they hold the blueprint for how to live long and successfully healthy lives.”


    “I got my first grant, looking at how it is that they're able to live 17 years. Little did I know then that these animals would be exceeding 39 years of age in my care.”


    “The fact that these animals don't seem to show any age-related change in cardiac function to me is remarkable. If we could understand the mechanism behind that, we might be able to come up with ways to improve human heart function and human health.”


    “[Naked mole rats] seem to be resistant to just about everything.”


    “We think that the mechanisms that protect them against aging might be the same as some mechanisms that protect them against cancer as well.”


    “We know that broccoli and the cruciferous vegetables all upregulate Nrf-2 naturally.”


    “I think the traditional model organisms have played a very important role in understanding aging. Because while evolutionary distance all of these models share an important feature, and that is, as they get older, their health declines and their probability of dying increases.”


    “I think that yes, we've learned a lot from mice, and we've learned how we can manipulate aging or health span, to some extent, but nowhere near the extent that you could, by looking at species that have already over a multimillion year evolutionary process, modified their biology and have features that enable them to live 10 times longer than a mouse. And that's where I think the naked mole rats are an important model.”


    “The real answer is we don't really know what it is that kills them. We just know what doesn't kill them are the common diseases that kill mice and rodents.”


    “Every time we've tried to induce some kind of stress, we see a very abrogated or attenuated inflammatory response. They don't seem to activate their inflammatory pathways to the same extent as other animals.”


    “Unlike mice, which have predominantly lymphoid cells, T cells and B cells, naked mole rats tend to rely much more on the innate immune system, on the myeloid cells.”


    “Both humans and more rats have about 40% of their immune cells being the slow responding adaptive immune cells.”


    “Any female in the colony can breed, but most of them are stuck in the suspended prepubescent state. When a female becomes the dominant breeding female, she continues to breed throughout her life. There's no sign of menopause.”


    “In most species, fertility declines as you get older. It's true of mice, and it's true of humans. And yet mole rats are showing the exact opposite pattern where the number of offspring produced in a litter increases with increasing age.”


    “The naked mole rat can survive 18 minutes in an oxygen-free environment without damaging its brain in any way. Whereas humans and mice after three minutes are brain dead.”


    “I think many of the effects that we see that pertain to their extreme longevity are byproducts of having to cope with such a harsh and hostile environment.”


    “The biology of the naked mole rat provides a proof of concept that it contains a blueprint for how to stave off many of the adverse effects of aging. The real problems with trying to figure out what that blueprint is.”


    “To me, the next steps are trying to successfully make transgenic naked mole rats, and being able to manipulate certain genes both in them, and giving their unique genetic makeup to mice to see if we can extend their longevity, or at least their health span in a significant kind of way.”



    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Calico Labs Website calicolabs.com




    Building networks and community around aging research (Leanne Jones and Saul Villeda of the Bakar Aging Research Institute) Sep 29, 2021
    Show notes

    Earlier this year, the University of California San Francisco launched the Bakar Aging Research Institute (BARI), a scientific community that aims to translate breakthroughs in aging research across many disciplines into new approaches and treatments that help people remain healthy and vibrant in later life. Here to tell us about the Institute are Professor Leanne Jones, who moved from UCLA to UCSF to serve as Director of BARI, and Associate Professor and Associate Director of BARI, Saul Villeda. Today Dr. Jones and Dr. Villeda join host Chris Patil to discuss the mission and structure of the Institute, as well as their goal to bring people from different campuses together to push forward the field of aging research as a whole.

    Dr. Jones and Dr. Villeda talk about the collaborative culture at UCSF, lowering barriers to resources across disciplines, and what inspired the idea behind the Institute. They explain how they plan to foster communication between basic scientists, clinicians, and healthcare workers to enhance translational medicine, as well as the pathway to commercialization for BARI, and the value of building a community around improving human health together. Finally, Chris asks Dr. Jones and Dr. Villeda about the greatest challenges they’ve had to overcome in starting the Institute, their top priorities moving forward, and what they’re most excited to achieve through BARI over the next five to ten years.


    Episode Highlights:

    • Mission and structure of the Bakar Aging Research Institute (BARI)
    • Responsibilities and benefits of membership in the institute
    • Connecting researchers across campuses
    • Network creation and community creation
    • Spirit of community will help attract other institutions to collaborate
    • Providing central resources and lowering barriers to research
    • What inspired the Institute and founding vision of Barbara Bakar
    • How BARI will enhance and promote translational medicine, translational applications
    • Improving communication amongst scientists, clinicians, and healthcare workers who are interested in treating problems related to aging
    • QB3 is a University of California hub for innovation and entrepreneurship in life science
    • Path to commercialization for BARI
    • Value of communicating with the community and including everyone in the conversation about improving human health
    • Biggest challenges Dr. Jones and Dr. Villeda have had to overcome in getting BARI started
    • Building a tangible community through a hybrid system of virtual/in-person interactions
    • Top priorities moving forward and what they hope BARI will achieve in the next five to ten years
    • Investing in the community and helping people jumpstart their research programs (e.g., Sandler Fellows Program)


    Quotes:

    “Our mission is broad, and really focused on building networks and community around aging. And, as we've said, improving the outcomes for older adults.”


    “It's exciting to think that our original vision of bringing people together from across all of the campuses is really coming to fruition.”


    “The requirement is that you're a full-time faculty member or equivalent at UCSF, and membership brings an ability to have first priority for funding opportunities, as well as the core resources that we're building up currently.”


    “What we quickly realized is that there are a lot of existing resources that people just don't know about. There was no centralized place, where you could just send an email and say, Hey, is anyone in Geriatrics...collecting blood from aging people?”


    “That's really one of the main things I think that people will get out of this - it's sort of a central place where you can make connections to facilitate and push your research forward.”


    “We really took it on as our charge to provide all of these resources for the community at UCSF, so that there's really lowering of any barrier to do the type of research that's related to the biology of aging, and also health span, and improvement of health ultimately, within the community.”


    “We're starting locally. But hopefully, we'll have an impact beyond the UCSF campuses soon.”


    “Really, I think that's the essence of the entire Institute is this idea of community.”


    “Here we have an institution where everyone is so close to each other, they have all the expertise, that just by building a series of bridges, I think we'll have an entire roadmap from beginning to end.”


    “We are improving the ability of everyone to take their discoveries, and hopefully have a much wider and a much more long lasting impact.”


    “We're really leveraging some of these resources to both facilitate questions that people have wanted to ask for a long time, but maybe didn't feel that they have the support to do it.”


    “We decided then that an institute would be the best way to sort of transfer this idea of community in a very tangible way across UCSF.”


    “In terms of infrastructure, we're trying to already lay the groundwork for setting up a program to do translational studies.”


    “We've got basic biologists, clinicians talking already, we are providing resources and funding for collaborative studies between these groups. And we're trying to go ahead and think about how we can provide a framework for translational neuroscience at UCSF.”


    “UCSF is a public university, and our mission is human health. And we want to be able to interact with and connect with the community.”


    “One thing that worked in our favor was actually the fact that we have been virtual for almost two years now, and that facilitated a number of town halls.”


    “What I'm really hopeful that we will be able to do is to be a place where an individual can come to get a personalized plan for improving their health or for maintaining their health.”


    “Every time you bring in someone new, it changes the landscape. So that makes me excited.”


    “I have no doubt the seeds that we are planting and sowing right now will really prove to be fruitful in the next five years.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Bakar Aging Research Institute (BARI) Website geroscience.ucsf.edu



    Gene therapy screening to discover aging targets (Martin Borch Jensen - Gordian Biotechnology) Sep 15, 2021
    Show notes

    Gene therapy screening to discover aging targets (Martin Borch Jensen - Gordian Biotechnology)

    Gordian Biotechnology is a San Francisco Bay Area biotech company that has created the first in vivo therapeutic screening platform aimed at drug development for complex diseases of aging. Co-founder and Chief Science Officer, Dr. Martin Borch Jensen joins the show today to discuss Gordian’s unique in vivo pooled screening in animals, as well as which indications they are targeting, their strategy to bring drugs to market, and how Gordian is currently tackling the challenges inherent to animal models. Martin also speaks about his passion from an early age to help fight age-related disease, and making the transition from academia to entrepreneurship, giving up a K99 fellowship at the Buck Institute for Research on Aging to make the jump into biotech.

    You’ll also hear about Martin’s involvement in multiple efforts to promote longevity science and bring new people into the field, including his apprenticeship program, the newly announced Longevity Impetus Grants program, and recording his “Science of Aging” seminar. Next, Martin shares what’s next for Gordian as they get ready to scale to the next level, which areas of longevity science he is most interested in but not currently working on, and how he predicts the field will evolve over the next five to ten years. For more information on Martin’s apprenticeship program and Impetus Grants application process, please visit MartinBorchJensen.com or follow him on Twitter.

    Episode Highlights:

    • Dr. Martin Borch Jensen is the co-founder and CSO of Gordian Biotechnology
    • Gordian Biotechnology created the first in vivo therapeutic screening platform to radically improve drug development for complex diseases of aging
    • Martin is also involved with an apprenticeship program and a newly announced grant program to catalyze rapid progress in aging research
    • How Gordian’s unique in vivo pooled screening in animals works
    • They’re focused on removing the diseases of aging, beginning with their three lead indications, NASH (nonalcoholic steatohepatitis or fatty liver), osteoarthritis and idiopathic pulmonary fibrosis
    • How Gordian compiles their gene libraries
    • While other companies start with in vitro models and then figure out ways to test them in living animals, Gordian starts with the second step
    • They deliver hundreds of gene therapies at once to a single animal
    • The drugs that they ultimately develop won't necessarily be gene therapy, but instead whatever is most appropriate to pursue the indication once they know the target (small molecule drugs, antibodies)
    • What a cell needs depends on what a cell is
    • Gene therapy has plenty of advantages, but the cost is very high
    • How Gordian is overcoming challenges that are inherent to animal models
    • Older mice are much more expensive and are rarely used in aging research
    • Animal models can actually be useful if the animal has progressively developed a disease in the same way humans do, and has similar biology
    • Example of studying osteoarthritis in horses, because the load-bearing structure of their joints is much more similar to humans, as is their cartilage thickness
    • Gordian’s strategy to bring drugs to market
    • Martin’s transition from academic to entrepreneur and what inspired him make the jump to biotech
    • He gave up a K99 fellowship at the Buck Institute for Research on Aging
    • He realized as a teenager that he wanted to try to fix aging
    • Martin is good friends with Dr. Kristen Fortney, co-founder and CEO of BIOAGE; her journey showed him that it was possible to start his own company
    • Martin is also involved in multiple efforts to promote longevity science, and to bring people into the field
    • His apprenticeship program was developed as a way to bring people in, and train them to be able to work on direct projects
    • Longevity Impetus Grants is a $21 million (update: $26 million as of the release of the podcast) program that provides funding for scientists to start working on what they consider the most important problems in aging biology without delay
    • This was inspired by COVID-19 “Fast Grants,” created by Tyler Cowen, Patrick Collison, and Patrick Hsu
    • Their goal is to take big bets on projects that could move the field forward, and recipients will be able to publish their findings regardless of what their results are
    • Impetus Grants applications open on Monday, September 13, 2021
    • Martin also recorded a comprehensive seminar about the science of aging
    • What’s next for Gordian as they get ready to scale to the next level
    • Martin predicts that in 5-10 years, we will have ways of measuring biomarkers for aging in humans


    Quotes:

    “It's phenotypic screening, but also because it's gene therapies we're putting in, we know the target immediately. So I call it ‘pheno-target screening,’ combining the best of both discovery modalities that are used.”


    “At Gordian, we're focused on removing the diseases of aging. Right now we're doing that with three lead indications, and that number will grow, which are NASH and osteoarthritis and idiopathic pulmonary fibrosis.”


    “We've created the platform in order to be able to do somewhat unbiased screens or entirely unbiased screens, and just explore a lot more of the biology of these diseases than has ever been explored in vivo so far, because we have this higher throughput.”


    “The logistics of the other method simply don't allow you to test a wide range of things in the in vivo context.”


    “I'm very excited about gene therapy in the long run to treat aging, diseases of aging, and just the physiological processes of aging. Because it turns out that what a cell needs depends on what a cell is. And so you probably don't want the same treatment in every type of cell in your body.”


    “You need a targeted way to go in and give each type of cell and each tissue what it needs, if we're going to really exercise control over the aging process.”


    “Maybe animal models aren't so bad for many diseases, if you find an animal that has continuously developed, progressively, a disease in the same way that humans develop this disease, and has biology that resembles human biology and the relevant organ.”


    “We are a drug development company. We've developed this in vivo full screening platform in order to use it ourselves and discover the best drugs for each of the indications that we go into.”


    “We are in conversations with a whole bunch of pharma companies about partnering at the clinical stage around the assets that we are discovering with our platform.”


    “As a teenager, I came to the realization that I wanted to try to fix aging… The idea that everyone is going to get sick and be in pain, and then die, just seemed really bad.”


    “I wanted, with Gordian, not only to have the successful outcome of treating age-related diseases, but I also wanted to feel for myself that I was doing absolutely everything that I could towards the goal that I had decided.”


    “It's going to be really hard. There's going to be doubts and challenges… And so if you're doing it for reasons that won't compel you to push through all of that, it's probably not going to work out.”


    “[This apprenticeship program] is needed, because there are more things that should happen, and apparently could happen, than I could possibly ever go and do myself.”


    “The apprentices end up doing most of the legwork by far. And I'm kind of steering it.”


    “This is the real test of success for this apprenticeship - if the people in it end up running important projects within the longevity field overall, then it's a success.”


    “If there is something there, if the project does work out, that would actually be a really big push forward for the field, then we should try to fund those things. And many of them won't work out and that's okay. We can learn from that.”


    “Any nonprofit can apply from anywhere in the world. Or any researcher at a nonprofit.”


    “What you really have to explain to us is, How is what you're doing going to move the field forward, if it works, and why is the way that you're doing it, a good, robust, well thought-out experimental plan for doing it? Those are the main things that we look for.”


    “In five to 10 years, I think we will have drawn studies for biomarkers of human aging. So I think that in five to 10 years -hopefully more like five - we will have ways of measuring in humans, something that we choose to call aging.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Martin Borch Jensen Website MartinBorchJensen.com


    Martin Borch Jensen on Twitter: @MartinBJensen


    Longevity Impetus Grants Website ImpetusGrants.org


    Gordian Biotechnology Website Gordian.bio



    Changing the Narrative on Women’s Reproductive Longevity (Dr. Jennifer Garrison, Buck Institute & GCRLE) Sep 01, 2021
    Show notes

    On today’s episode is Dr. Jennifer Garrison, Professor at the Buck Institute for Research on Aging, and the Faculty Director of the Global Consortium for Reproductive Longevity and Equality (GCRLE), which is devoted to supporting breakthrough research on reproductive aging and women in science through funding, training, infrastructure, and collaborative intellectual networks.

    Dr. Garrison explains that while there are plenty of scientists working on aging and plenty who are working on reproductive biology, there are precious few who are working at the interface of these two fields, which is what they are trying to build at the GCRLE. She shares her fascination with ovarian biology and how it fits into the broader context of longevity research, and details the issue of equality in terms of women having to plan their life choices around reproductive longevity in ways that men do not, as well as funding for women’s health being traditionally overlooked. Dr. Garrison answers questions about menopause across the animal kingdom, the link between reproductive span and lifespan in women, and the most important question we need to answer in order to truly understand ovarian aging.

    Dr. Garrison describes the key role played by the brain in reproductive success, the need for better animal model systems to understand menopause, and how hormone replacement therapy can help mitigate the negative health consequences around menopause. You’ll also hear about the profound economic and societal impact of menopause globally, as well as Dr. Garrison’s goals for the future and dream outcomes she envisions for the Consortium as they continue their cutting-edge research on the causes of ovarian aging. To learn more about their important work, visit BuckInstitute.org/gcrle/.


    Episode Highlights:

    • The goal of the Global Consortium for Reproductive Longevity and Equality (CGRLE) is to extend the female reproductive span
    • The Global Consortium began at the Buck Institute for Research on Aging through a generous donation from Nicole Shanahan and the Sergey Brin Family Foundation
    • There are plenty of scientists working on aging and others who are working on reproductive biology, but precious few who are working at the interface of those two fields - that’s what they are trying to build
    • The GCRLE has three arms: Funding; providing resources to build out the field; and building a network communications platform to foster dialogue and collaboration among researchers working on female reproductive aging
    • They’ve also opened the world’s first ovarian biology core facility at the Buck Institute
    • Ovaries are a very complex structure, and they age at a precocious rate - they’re considered geriatric by the time a woman is in her late 20s, early 30s
    • Nicole Shanahan’s became involved with starting the CGRLE to find out what causes ovaries to decline in function so early
    • Ovarian biology as it relates to reproductive longevity has been traditionally overlooked in terms of receiving funding
    • Women’s health has been looked at as a subcategory of medicine
    • Equality is a key piece to what they do - women need to plan their life choices around reproductive health in a way that men do not
    • Menopause accelerates the aging process
    • It is relatively rare in the animal kingdom - humans are one of the only species that go through menopause
    • Women who experience menopause later in life also tend to live longer and have an enhanced ability to repair their DNA
    • There is a clear link between reproductive span and lifespan in women
    • The key question is, What is the cue that tells a woman’s ovaries to start declining in her 20s?
    • The brain is a crucial player in reproductive success
    • We need better animal model systems to understand menopause
    • Female reproductive health trajectory and how medical intervention fits in
    • Hormone replacement therapy is one of the best band aids we have to mitigate the negative health consequences of menopause
    • Studies show that there is a positive benefit to doing hormone replacement therapy on cognitive function
    • Economic impact of menopause and related healthcare costs
    • Emerging trend of reproductive aging in biotech industry
    • Dr. Garrison’s goals for the future and dream outcomes she envisions for the Consortium


    Quotes:

    “We started a few years ago, with a really generous gift from Nicole Shanahan and the Sergey Brin Family Foundation. We started a center at the Buck Institute to study female reproductive aging.”


    “When we started the center, we realized right away that if we really wanted to have an impact, and truly move the needle, that we were going to have to do something bigger. And that's where the consortium came in.”


    “What's different about the ovary, compared to every other organ in the human body, is that it ages precociously, meaning that it's actually the first organ by far to age in the human body, and it's aging at about two and a half times the rate of the rest of the tissues.”


    “I think research on women's health is underfunded in general.”


    “I think that as we make progress and advances in extending healthy longevity and health span, or the number of years that someone's healthy, if we don't address reproductive longevity, then I think gender inequality is going to get worse, not better.”


    “From the minute I went through puberty, whether I wanted to have biological children or not, every decision that I made was overshadowed by the fact that I was going to go through this reproductive decline in midlife - this biological clock, so to speak, that was ticking in the background. Decisions about overall health, my career, family planning. This is an issue of equity. Men don't have these concerns.”


    “Humans are really weird. We're very unusual as a species. There's almost no other species - there's very few species that go through menopause.”


    “Women who have later menopause tend to live longer. They also have an enhanced ability to repair their DNA.”


    “There's no question that the brain is a key player for reproductive success. It controls all aspects of female reproduction: Puberty, menstruation, fertility, conception, pregnancy, childbirth, childcare, and ultimately menopause.”


    “That's the goal is to give women more choice and control over their own bodies.”


    “By the time a woman actually might want to use her ovaries, she's left with approximately 2 to 3% of the number of eggs that she started with.”


    “The bottom line is that hormone replacement therapy is probably the best band aid we have to mitigate the negative health consequences of menopause.”


    “I think the basic science has to happen first. I can't emphasize that more strongly. Otherwise, like I said, everything we're doing is a band aid.”


    “I really want people to think about a scenario where women aren't constrained by an immutable biological clock, to think about a world where women aren't subject to the detrimental health effects of menopause. And just to consider for a moment, the implications for social, economic and personal empowerment, that that freedom of choice and freedom from health risks would give to half the population.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Global Consortium for Reproductive Longevity and Equality Website buckinstitute.org/gcrle/


    Garrison Lab Website garrisonlab.com



    The Cures Within Us (Hanadie Yousef — Juvena Therapeutics) Aug 18, 2021
    Show notes

    Dr. Hanadie Yousef is a scientist, aging biology expert and the co-founder and CEO of Juvena Therapeutics, a Palo Alto-based biopharma startup developing protein-based therapeutics to promote tissue regeneration and increase healthspan to prevent, reverse, and cure degenerative diseases.

    Dr. Yousef joins host Dr. Chris Patil to discuss Juvena’s premise, their use of a machine learning platform to identify proteins that have therapeutic potential, and what most excites her about turning signaling proteins into therapeutics. She answers questions about handling potential challenges within Juvena’s approach, their strategy for bringing drugs to market, and the first aging indication that they are targeting - muscular rejuvenation. Dr. Yousef outlines Juvena’s plans for a clinical study in patients with Myotonic Dystrophy Type 1 by 2023, and shares what’s coming down the pipeline next for her team. You’ll also hear about Dr. Yousef’s transition from academic science to becoming an entrepreneur, her involvement with the On Deck initiative, which seeks to increase the number of scientists, researchers, and inventors in the healthspan and longevity field, and why it’s so worthwhile to invest in anti-aging science.

    The interview concludes with Dr. Yousef’s advice for potential new founders in the biotech industry. She also shares the areas of longevity science that she is most fascinated by, and offers her thoughts on how the field of aging pharma will evolve over the next five to ten years.

    Episode Highlights:

    • Tissues deteriorate as we get older and our ability to heal slows down - this leads to a wide variety of age-related diseases
    • Juvena Therapeutics sets out to find regenerative cures for those diseases
    • During the aging process, critical regenerative protein signaling pathways that are important for instructing cells and tissues within our bodies start to change
    • They start becoming over-expressed or under-expressed
    • There is a change and loss of healthy crosstalk between pathways that can instruct cells
    • This leads to a loss of tissue homeostasis
    • By understanding what is changing within us, we can use that information to target protein signaling pathways that are important for stem cell function, immune cell function, etc. in order to rejuvenate tissues and reverse the aging process
    • Juvena uses a machine learning platform by combining several data modalities
    • Their premise is to develop protein-based therapies that can target critical regenerative signaling pathways in our bodies to promote better regeneration
    • They do this by mining secretome of the most po-regenerative source of cells, which are human embryonic, or pluripotent, stem cells
    • Aging models that they use are cells derived from people who are themselves aged or who have an age-related disease
    • There are challenges with every therapeutic intervention targeting the biology of aging
    • Juvena’s strategy for bringing drugs to market and the first aging indication they are targeting
    • They are looking to promote tissue-specific rejuvenation, for example, better muscle differentiation, reduced atrophy and improved strength and function
    • They are hoping to have FDA approval as an investigative new drug within the next year and a half - this would lead to a Phase One/Two clinical study for patients with Myotonic Dystrophy Type 1 by 2023
    • Dr. Yousef’s academic background and transitioning to starting her own company
    • She has a passion for both drug discovery and taking those inventions to build companies
    • The inspiration and motivation behind starting Juvena Therapeutics with co-founder Dr. Jeremy O'Connell, as well as the process of pitching and acquiring funding
    • Dr. Yousef was torn between an academic career and entrepreneurship, and she ultimately decided to embrace her role as CEO and focus on building the company
    • How investors react to Juvena Therapeutics’ aging focus and how Dr. Yousef puts their minds at ease with regards to the expense of biotech and therapeutic investment
    • It’s worth the risk - with a looming healthcare crisis of an aging population around the corner, the company that succeeds in anti-aging science could be one of the most lucrative and successful companies in the world
    • Dr. Yousef’s involvement in the On Deck initiative - a fellowship program that seeks to increase the number of scientists, researchers, and inventors in the healthspan and longevity field
    • Advice she would give new entrepreneurs in this field
    • She is fascinated by the study of human centenarians, reproductive aging, and plant aging
    • Her predictions for the field of aging pharma in the next 5-10 years


    Quotes:

    “As we all know, tissues deteriorate as we get older, and our ability to heal slows down, which leads to a wide range of age-related diseases. So Juvena Therapeutics sets out to find regenerative cures for these disorders.”


    “Through years of dedicated research, we discovered that the cures had been within us all along.”


    “By understanding what is changing within us, we can actually use that understanding to target those protein signaling pathways that are so important in regulating stem cell function, immune cell function, tissue regeneration and repair, in order to rejuvenate tissues, and to actually reverse the aging process and to bring our bodies back internally to a more healthy state.”


    “Ultimately, our premise at Juvena is to develop protein-based therapies that can target these critical regenerative signaling pathways in our bodies to promote better regeneration.”


    “What we're doing with our machine learning enhanced platform is really building a map of regenerative protein biology with a compounding database that's enabled by an array of in-house machinery and computational tools that we establish using these data modalities, to really identify the proteins that have therapeutic potential.”


    “What excites us about actually turning signaling proteins into therapeutics is their ability to really interact in more of a systems biology level with multiple pathways.”


    “Of course, ultimately, the goal is to calibrate homeostatic levels of signaling to more youthful levels, and not try to over induce any one particular pathway. And so by really recalibrating, and being careful about dosing, we'll be able to avoid things like oncogenic transformation.”


    “We are, right now, really interested in bringing our muscle regeneration protein therapeutic to market for a rare neuromuscular, muscle wasting disease, known as Myotonic Dystrophy Type 1.”


    “Our hope is that by 2023, we will be conducting what would be a combined Phase One/Two clinical study for patients with Myotonic Dystrophy Type 1 to test if our regenerative therapeutic can, in fact, do what it's doing in all the models and all the preclinical data to date.”


    “What's really coming is our ultimate goal of enhancing and promoting health span, and reversing multiple age-related and chronic diseases by developing a pipeline of protein therapies that act by rejuvenating your own body endogenous stem and precursor cell function to enhance regeneration and improve and rejuvenate your life.”


    “I am a neurobiologist, stem cell biologist and aging biologist by training.”


    “What came first for me was really a passion in general and biomedical research, and in the startup environment and in building companies.”


    “I really fell in love with the concept that actually understanding the mechanisms driving the aging process, and specifically, the changes in signaling that occur that lead to loss of stem cell function with age, we can actually use that understanding to reverse the process, to rejuvenate stem cell function to revitalize the body, and to then really reverse aging. And so that got me so excited. And I just fell in love with that and knew that that is what I want to dedicate the rest of my life to doing.”


    “It was this battle for me of, I love my research, I can really envision myself leading an academic lab and a faculty position to move this forward, really focus on brain aging. But then there was this also entrepreneurial opportunity to start my company and to instead really focus more on translational work, and really building the platform that enables a pipeline of protein therapeutics.”


    “The other things investors fear is just the expense associated with some of these indications.”


    “In the next decade, the largest demographic of people will be those over the age of 60. I think it's really in investors that just realize, it's worth the risk. Because the company that succeeds will be potentially one of the most lucrative, successful, and sought-after companies in the world.”


    “Some advice I wish I had going into this is really looking at what the target product profile of a drug you want to develop is, and as early as possible, creating a plan to really get to that preclinical stage in that translational stage where you need significantly more investment.”


    “I think in five to ten years, we'll get increasing acceptance of aging as a risk factor to diseases and more of an acceptance of therapeutics that can target the aging process.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Juvena Therapeutics website



    The Dog Aging Project: Understanding longevity in our canine companions Aug 04, 2021
    Show notes

    The Dog Aging Project is an innovative initiative that brings together a community of dogs, owners, veterinarians, researchers, and volunteers to carry out the most ambitious canine health study in the world. The goal of the Dog Aging Project is to understand how genes, lifestyle, and environment influence aging, and to use that information to help pets and people increase their healthspan, the period of life spent free from disease.

    Co-directors Dr. Daniel Promislow and Dr. Matt Kaeberlein join the show to discuss the origins of the Dog Aging Project, the overall goals for their initiative, and why dogs are a particularly good model for human aging. They talk about their funding through the National Institutes of Health, the extensive scale of the Dog Aging Project, and its “Community Scientist” component, with canine participants still living at home with their owners. Professors Promislow and Kaeberlein explain their use of molecular biology measures to predict health outcomes for dogs, their commitment to making their data available to the scientific community as a whole, and the difference between how small dogs versus large dogs age, as well as what diseases or conditions different breeds age and die from.

    Today’s fascinating conversation also touches on the impact of living in a rural versus urban areas on aging, how veterinarians feel about participating in the Dog Aging Project, the test of rapamycin in aging dogs (TRIAD), and the intrinsic value of being able to increase the lifespan and healthspan of our pets. Professors Promislow and Kaeberlein share what drew them to the field of aging, and review the importance of putting safety first in their work with dogs. Finally, you’ll hear their exciting predictions for what we can expect to see in aging research over the coming decades.

    For more information on the Dog Aging Project, visit DogAgingProject.org. Thank you for listening.


    Episode Highlights:

    • Professors Daniel Promislow and Matt Kaeberlein are co-directors of the Dog Aging Project at the University of Washington in Seattle
    • Dog Aging Project started in 2007 to investigate whether IGF-1 was associated with aging for dogs
    • Chief Veterinary Officer is Kate E. Creevy
    • Overall goals are to understand how genes, environment, and lifestyle shape healthy aging in dogs and the mechanisms by which they do so, and to determine whether we can intervene and improve healthy aging in dogs
    • Dogs are a very good model for human aging due to their similar environment (water quality, air quality, home setting)
    • Dogs age seven to 10 times more rapidly than humans do, which means we have better success carrying out longitudinal studies with them
    • They also get the same types of diseases that we do
    • The Dog Aging Project is funded through the National Institutes of Health, and in particular, the National Institute on Aging
    • The scale of this project is notable, as well as the fact that the dogs are not in laboratories, but are living at home with their owners
    • It’s a “Citizen Scientist” or “Community Science Project” effort
    • They now have upwards of 32,000 owners and dogs participating, and are still enrolling at DogAgingProject.org
    • They collect information about the dogs’ health, disease, activity, diet every year, over the course of their entire lives
    • These molecular biology measures will allow them to predict what might happen in the future for dogs, and to improve diagnosis and prognosis
    • The samples are also stored in a biobank at Cornell, with the hopes that can be useful in studying overall aging as time goes on and new technologies become available
    • The Dog Aging Project has always been an open science project, with data being made available to the scientific community on an annual basis
    • The rate of aging for dogs varies depending on size and breed
    • Biological aging is faster in dogs than in humans, but the relationship is not necessarily linear
    • What different breeds die of is very different
    • Large dogs frequently die of Osteosarcoma, which is rare in smaller breeds and humans
    • Certain organs may age faster than others
    • The Dog Aging Project is able to control for different breeds using their genetic data
    • Dogs who live in rural areas spend more time outside and engage in more physical activity - soon we will be able to tell how this affects the aging process
    • Veterinarians are very enthusiastic about participating in this study
    • Test of rapamycin in aging dogs (TRIAD) clinical study looks at whether or not the drug Rapamycin can slow aging and increase healthy lifespan in dogs
    • Translating this to humans and bridging this to human trial
    • If they find success in increasing the healthspan of people’s pets, this could really change the way the field is perceived by the general public
    • Challenges of collecting and curating massive amounts of data
    • Dogs who were administered rapamycin became more active afterward
    • How Professors Promislow and Kaeberlein became interested in the field of aging
    • Dogs are becoming increasingly important models for understanding human health
    • Safety is always first priority for the animals
    • Professors Promislow and Kaeberlein share their predictions for aging breakthroughs and challenges in the coming years
    • We will see advances in biomarkers or “precision geroscience” in the next decade
    • It’s important to have realistic expectations and use consistent language when discussing aging - to use the term “curing aging” or “defeating aging” is misleading


    Quotes:

    “Dogs experience pretty much every aspect of the human environment.”


    “Dogs have the advantage, from the perspective of trying to understand aging, that they age about seven to 10 times more rapidly than people do. So that means that we can actually carry out longitudinal studies to understand the most important genetic and environmental risk factors in a few years, whereas in people it would take a few decades.”


    “A lot of what we know about human health and disease, we’ve learned from really simple organisms, like yeast, and nematode worms, and fruit flies.”


    “There is no upper limit. We hope to continue this project for many generations of dogs.”


    “The first, most important level is just to collect the information about health, disease, activity, diet from all the dogs. That's done through surveys, and all participants will be asked to contribute survey updates every year, so we follow the dogs throughout the course of their lives.”


    “Our scientists will also analyze what we call the Systems Biology Components - the epigenome, the microbiome, the metabolome. We're also looking at a panel of inflammatory markers, measuring frailty. So these are the sorts of things that we will track throughout the course of the life of these dogs. The hope is that these molecular biology measures that we collect will allow us to predict what might happen in the future for dogs and to improve diagnosis, and prognosis as well.”


    “Our expectation is that the samples that are collected and stored in the biobank will be useful to the field for exploring those other types of molecular markers that may be particularly predictive for overall aging, or certain age-related disease processes.”


    “The Dog Aging Project, from its inception, has been envisioned as an open science project. And so all of the data that we collect is being made available on an annual basis to the scientific community.”


    “The other thing about dogs is that a decade from now, when new technologies may be available, that's about the equivalent of 70 years of biological aging in people. So it's almost as if any human longitudinal study you had biobank samples for seven decades, we can get that sort of biological age resolution in a single decade of dogs.”


    “A Great Dane would be considered geriatric at seven years, whereas a Chihuahua might be considered geriatric at 12 or 14, and could very well live 18 or 19 years.”


    “The Dog Aging Project will eventually be able to tell us what the relationship is between the epigenetic age clock and actual aging of pathophysiological processes.”


    “There's just a lot to learn about how quickly different breeds age and what they age and die from.”


    “We shipped a kit to an owner to take to their veterinarian. And these kits are filled with, as I mentioned earlier, blood samples, hair, fecal samples, urine, and then they need to be delivered via FedEx, to our diagnostic lab. This was a rural veterinarian, and there wasn't a FedEx Office or drop-off point in that community. So the veterinarian, not the owner, but the veterinarian after work, drove 40 minutes to the next town over where there was a FedEx drop-off, so that they could deliver the kit. That's the kind of enthusiasm that we see from participating veterinarians.”


    “TRIAD is the Test of Rapamycin in Aging Dogs. That’s the only clinical trial the Dog Aging Project is carrying out right now. And the goal of that trial is really to test whether or not the drug Rapamycin can slow aging and increase healthy lifespan in dogs.”


    “Everybody on the Dog Aging Project team agrees that this isn't only about what we'll learn about human aging. There's intrinsic value in being able to increase the lifespan and healthspan of our pets. There's value to the pets and there's value to the owner.”


    “I think if we're successful in showing that it is possible to increase healthspan in people's pets, that will really be a watershed moment in the field in the way that we are perceived by the general public.”


    “There are lots of wearable devices on the market for dogs. And they're very much like the devices that humans were, typically though they go on the collar of the dog. And we will be putting those devices on the Precision dogs and the TRIAD dogs to measure their activity, how it changes with age.”


    “There are several companies now that are trying to develop therapies to treat aging or age-related indications with companion animals, at least as the first path to the market. Me personally, I think that's fantastic. Certainly, we view the Dog Aging Project as something that hopefully other people in the field will build off of.”


    “We would just want to encourage all of the companies that are considering moving forward in the companion animal space to keep that in mind, and make sure that whatever you are planning to bring to the market, that you do it in the context of safety. Because the last thing that any of us want to do is harm somebody's pet.”


    “We're excited to try and recruit these diverse populations to the Dog Aging Project, and maybe even to use that as a model for getting all communities excited about participating in this term that we'd like to use of ‘community science.’”


    “I fully expect that within the next decade, we will see the first geroscience intervention approved to treat an age-related indication.”


    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Dog Aging Project Website DogAgingProject.org


    Giving our best friends more time: Healthy aging for dogs (Celine Halioua, CEO of Loyal) Jul 21, 2021
    Show notes

    Loyal is a San Francisco-based startup that is seeking to treat the underlying causes of aging in dogs. Loyal has raised $11 million in seed funding so far, and is planning to start clinical trials of medications in 2022 and 2023. In this episode, BioAge VP-Media Chris Patil talks with Celine Halioua, CEO and founder of Loyal.

    Celine beginswith by describing the striking difference in lifespan among the dog species, with smaller breeds like the Chihuahua living twice as long as larger breeds like the Great Dane. She explains how historical inbreeding to create larger dogs actually caused them to age faster, and her plan to develop a drug that compensates for this accidental genetic disorder. Celine tells us about The Healthspan Study, which tracks aging markers in dogs, as well as what inspired her to start Loyal, and how their research complements the goals of the University of Washington Dog Aging Project. Celine breaks down the role of caloric restriction in anti-aging across species, why dogs are one of the best models for human aging as a disease, her background in neuroscience and longevity, and her passion for developing drugs for healthspan and lifespan extension. Celine also offers her perspective about encountering skepticism in the biotech industry, the unique challenges faced by young women founders, and overcoming sexist assumptions following the controversial story of Elizabeth Holmes. Finally, Celine shares what’s next for Loyal and her dream to build a consumer-focused pharmaceutical company that people love.

    To learn more about Loyal and their dedication to aging health for dogs, visit LoyalForDogs.com.


    Episode Highlights:

    • Loyal is seeking to determine why, on average, the larger a dog breed is, the shorter their lifespan
    • We do not see a 2X lifespan differential among varieties of other animals
    • Loyal also looks at ways to pharmacologically improve metabolic resiliency and fitness in aged animals to give them a longer, healthier lifespan
    • Historical inbreeding to create larger dogs led them to age faster once they were fully grown
    • Loyal is developing a drug that plans to compensate for this accidental genetic disorder
    • These drugs will enter clinical trials in 2022 to 2023
    • Loyal is also running “The Healthspan Study,” which tracks aging markers in dogs (register your dog here)
    • Dogs are like family to their owners, and Celine noticed how heartbroken owners were about their larger dogs aging and dying so early
    • This inspired her to start Loyal
    • Distinction between healthspan versus simply adding years to life
    • Thesis of Dr. Matt Kaeberlein of the University of Washington’s Dog Aging Project
    • Most breeds have some sort of predisposition for some sort of disease
    • LOY-001 specifically targets a cellular mechanism that is hypothesized to cause large and giant breed dogs to age faster and have shorter lifespans than their small-breed companions
    • They are also developing a second drug that is explicitly for dogs of any size, who have already shown signs of aging
    • Caloric restriction is one of the most fundamental agents of fighting aging - Loyal aims to replicate that effect with a drug, since most humans and dogs do not want to calorically restrict themselves
    • Veterinary drugs need to be approved by the Veterinary FDA (Center for Veterinary Medicine or CVM)
    • Dogs are one of the best models of human aging as a disease because they’ve largely evolved in the same environment as humans
    • Because dogs have a shorter lifespan than we do, we can see whether longevity-based drugs have an impact on lifespan more rapidly than in an animal with an 80-year lifespan (like humans)
    • Loyal has raised $11 million in seed funding - the largest amount for a woman solo founder
    • Her goal is to show that pharmacological interventions to extend lifespan and healthspan are incredibly valuable and worthy of investment
    • She has encountered skepticism in terms of both operational and societal barriers
    • Going against the current helps her company stand apart in startup culture, which has been beneficial for recruiting an amazing team, 70% of which is female; but she also has to go above and beyond to prove her competence
    • What’s next for Loyal and building a consumer-focused pharmaceutical company
    • If they can succeed in developing a dog aging drug, it can help humans as well
    • False fail risk
    • The aging industry has a communal feel, rather than competitive, as we’re all pioneers in the field and individual successes are everyone’s success


    Quotes:

    “Fundamentally, we're developing various drug products that are targeting various concerned mechanisms by which dogs age to try to give them healthier years.”


    “Specifically, our first two products are looking at one of the underlying reasons as hypothesized why smallest dogs like a Chihuahua can live 18 or more years, while Great Danes on average will live seven to eight years.”


    “The larger a dog is, on average, the shorter that breed’s median lifespan, and that's abnormal. We don't see a 2x lifespan differential in humans, for example, or really any other species.”


    “It's actually a consequence of historical inbreeding of dogs, that was selecting for certain phenotypes like size, that basically looks to have created almost a genetic disorder for aging in these dogs.”


    “The drug that we're developing is hoping to compensate for the accidental genetic disease that we gave these dogs that causes them to become larger...and causes them to age faster after they're fully grown.”


    “We are basically doing a cross-sectional, observational - that means no drug, no intervention - study, looking at large and small, old and young dogs. And the idea of this study is basically to correlate various aging biomarkers of interest for our drug programs, and also just out of interest in general, to various dog sizes, breeds and conditions.”


    “There are different flavors of dog owners. But in general, people love their dogs. They see their dogs as family. They see their dogs as their furry children in some ways.”


    “Our first drug, LOY-001, is specifically indicated for large and giant breed dogs and extending their lifespan and healthspan and intervening while the dog is healthy.”


    “Caloric restriction is one of the most fundamental agent interventions there is. So the question is more, How do you emulate that with a drug? Because obviously, people don't really want to calorically restrict themselves or calorically restrict their dog.”


    “It's commonly accepted in the field that dogs are one of the best models, if not potentially the best model of human aging as a disease.”


    “Because dogs have a shorter lifespan than we do, if longevity-based drugs are efficacious in dogs, we could see whether they have an effect on lifespan much more rapidly in an animal with a 15-year lifespan than in an animal with an 80-year lifespan.”


    “Really my thing from, basically when I was 18, was how to develop better medicines for the worst diseases. And the worst diseases that I have always focused on, and been most interested in, were age-delayed diseases.”


    “I felt very strongly that my goal was to explicitly develop a drug for healthspan extension and lifespan extension.”


    “It's really fundamentally what I'm trying to do is prove a point to the broader population, to the medical community, to the development community, that yes, pharmacological interventions to extend lifespan and healthspan are incredibly valuable, and worthy of investment.”


    “I think when I walk into a room, there’s not necessarily an assumption of competency. And I've definitely also felt a requirement of almost like perfection.”


    “I'm very careful with how I word things because it's very easy, especially as a female founder, to get labeled as cocky or overconfident. So I'm much more conservative in my language than I might naturally be.”


    “Basically, people don't have very positive emotions or feelings towards pharmaceutical companies, which is understandable on some variables, but also disappointing because I think we want people to be excited about spending time...and working on developing new medicines. It's, in my opinion, one of the most important things to spend your life on because health is fundamental.”


    “I'm really interested in the opportunity of building a pharma company that people love.”


    “Actually if you think about it, aging encompasses probably the majority of cancers, plus nerve center disorders plus sarcopenia, arthritis, all these other diseases.”


    “Honestly, every company that's legitimate, that works on aging is only more helpful. It makes my life a little bit easier to prove that it's a valid thing to work on.”


    “We all win if we develop better medicines, and that's kind of where it's supposed to go.”


    “I feel like my only job is to help develop better medicines. So it means everything to me because I think it's the most important problem to work on.”



    Links:

    Email questions, comments and feedback to podcast@bioagelabs.com


    Translating Aging on Twitter: @bioagepodcast


    BIOAGE Labs Website BIOAGELabs.com


    BIOAGE Labs Twitter @bioagelabs


    BIOAGE Labs LinkedIn


    Loyal website LoyalForDogs.com



    Previous 1 4 5 6 7 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights